AbbVie Reports Topline Data from P-III (TEMPO-1) Study of Tavapadon Alone for Parkinson's Disease
Shots:
- Abbvie has reported topline data from the P-III (TEMPO-1) study assessing the safety, efficacy & tolerability of tavapadon (5mg & 15mg, QD) alone to treat patients (n=529, 40-80yrs.) with early Parkinson's disease for 27wks.
- Study reached the 1 & 2EPs, showing improvedMDS-UPDRS Parts II & III combined score (-9.7 & -10.2 vs +1.8) and improved motor aspects of experiences of daily living (MDS-UPDRS Part II) at wk.26. Safety aligned with the previous studies, with mild to moderate AEs
- Full data will be highlighted at upcoming conferences and will form the basis of regulatory submissions. Topline results from the P-III (TEMPO-2) study are anticipated by YE’24
Ref: AbbVie | Image: AbbVie
Related News:- Cerevel Therapeutics Reports Results from P-III Adjunctive Study Evaluating Tavapadon for the Treatment of Advanced Parkinson’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
